Chlorpheniramine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
Chlorpheniramine | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | |
Chlorpheniramine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | |
Chlorpheniramine | hsa00500 | Starch and sucrose metabolism | 1.67E-02 | 2 | O43451, P06737 | MGAM, PYGL | More | |
Chlorpheniramine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
Chlorpheniramine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
Chlorpheniramine | hsa00600 | Sphingolipid metabolism | 4.77E-02 | 3 | Q9BX95, O14494, P06280 | SGPP1, PLPP1, GLA | More | |
Chlorpheniramine | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | |
Chlorpheniramine | hsa00730 | Thiamine metabolism | 5.29E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
Chlorpheniramine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
Chlorpheniramine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Chlorpheniramine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
Chlorpheniramine | hsa00983 | Drug metabolism - other enzymes | 3.09E-04 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | |
Chlorpheniramine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
Chlorpheniramine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
Chlorpheniramine | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | |
Chlorpheniramine | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | |
Chlorpheniramine | hsa03010 | Ribosome | 1.88E-02 | 6 | P62753, P25398, P32969, P62829, P18077, P36578 | RPS6, RPS12, RPL9, RPL23, RPL35A, RPL4 | More | |
Chlorpheniramine | hsa03013 | RNA transport | 2.12E-02 | 9 | P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | |
Chlorpheniramine | hsa03020 | RNA polymerase | 3.59E-02 | 2 | P30876, P62487 | POLR2B, POLR2G | More | |
Chlorpheniramine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
Chlorpheniramine | hsa03050 | Proteasome | 1.21E-02 | 1 | P28074 | PSMB5 | More | |
Chlorpheniramine | hsa03320 | PPAR signaling pathway | 4.33E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | |
Chlorpheniramine | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | |
Chlorpheniramine | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04012 | ErbB signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04014 | Ras signaling pathway | 3.65E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04015 | Rap1 signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04022 | cGMP-PKG signaling pathway | 3.15E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04024 | cAMP signaling pathway | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04062 | Chemokine signaling pathway | 3.98E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04064 | NF-kappa B signaling pathway | 1.60E-02 | 8 | P10415, O00463, Q04759, Q9UDY8, Q16548, Q13315, P24522, P09341 | BCL2, TRAF5, PRKCQ, MALT1, BCL2A1, ATM, GADD45A, CXCL1 | More | |
Chlorpheniramine | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04071 | Sphingolipid signaling pathway | 8.30E-06 | 9 | P04049, P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415, Q9UQC2 | RAF1, PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2, GAB2 | More | |
Chlorpheniramine | hsa04072 | Phospholipase D signaling pathway | 2.82E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04080 | Neuroactive ligand-receptor interaction | 2.16E-03 | 9 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P21730, Q16581, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, C3AR1, ADRB2 | More | |
Chlorpheniramine | hsa04114 | Oocyte meiosis | 6.23E-03 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | |
Chlorpheniramine | hsa04115 | p53 signaling pathway | 3.98E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | |
Chlorpheniramine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
Chlorpheniramine | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04141 | Protein processing in endoplasmic reticulum | 4.88E-02 | 4 | P18848, O60337, P11142, P07900 | ATF4, MARH6, HSPA8, HSP90AA1 | More | |
Chlorpheniramine | hsa04145 | Phagosome | 3.82E-03 | 8 | Q15080, P14598, Q13509, P68371, Q13488, P05164, O60603, P35443 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4 | More | |
Chlorpheniramine | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04210 | Apoptosis | 5.97E-04 | 11 | Q13315, P10415, O76075, P01375, Q9NR28, P24522, Q16548, P43234, P18848, Q14643, P04049 | ATM, BCL2, DFFB, TNF, DIABLO, GADD45A, BCL2A1, CTSO, ATF4, ITPR1, RAF1 | More | |
Chlorpheniramine | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | |
Chlorpheniramine | hsa04217 | Necroptosis | 4.24E-05 | 10 | P01375, P48023, Q14765, P07900, P15104, P05141, P01584, P0C0S5, Q99878, Q13557 | TNF, FASLG, STAT4, HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC14, CAMK2D | More | |
Chlorpheniramine | hsa04218 | Cellular senescence | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
Chlorpheniramine | hsa04270 | Vascular smooth muscle contraction | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | |
Chlorpheniramine | hsa04360 | Axon guidance | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04370 | VEGF signaling pathway | 2.77E-04 | 4 | P16298, Q05397, Q02750, P04049 | PPP3CB, PTK2, MAP2K1, RAF1 | More | |
Chlorpheniramine | hsa04371 | Apelin signaling pathway | 2.65E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
Chlorpheniramine | hsa04540 | Gap junction | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 9.61E-03 | 4 | Q13873, P04049, Q02750, Q86SE9 | BMPR2, RAF1, MAP2K1, PCGF5 | More | |
Chlorpheniramine | hsa04610 | Complement and coagulation cascades | 2.78E-03 | 1 | P0C0L4 | C4A | More | |
Chlorpheniramine | hsa04612 | Antigen processing and presentation | 2.09E-04 | 8 | P13765, P48382, Q14953, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
Chlorpheniramine | hsa04613 | Neutrophil extracellular trap formation | 1.62E-06 | 12 | P04049, P11215, Q13547, P04908, Q93077, P58876, P62807, Q16778, O60814, P68431, O43315, Q16539 | RAF1, ITGAM, HDAC1, H2AC4; H2AC8, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | |
Chlorpheniramine | hsa04625 | C-type lectin receptor signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04630 | JAK-STAT signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04650 | Natural killer cell mediated cytotoxicity | 5.84E-06 | 11 | P16298, P50591, P01375, P20963, Q02750, P04049, Q13241, P26718, P26717, Q14953, P26715 | PPP3CB, TNFSF10, TNF, CD247, MAP2K1, RAF1, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
Chlorpheniramine | hsa04657 | IL-17 signaling pathway | 2.73E-04 | 7 | P07900, P49841, P19875, P14780, P80188, P01375, P01584 | HSP90AA1, GSK3B, CXCL2, MMP9, LCN2, TNF, IL1B | More | |
Chlorpheniramine | hsa04660 | T cell receptor signaling pathway | 1.66E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04662 | B cell receptor signaling pathway | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04664 | Fc epsilon RI signaling pathway | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04666 | Fc gamma R-mediated phagocytosis | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
Chlorpheniramine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
Chlorpheniramine | hsa04720 | Long-term potentiation | 4.88E-03 | 4 | P16298, P51812, Q02750, P04049 | PPP3CB, RPS6KA3, MAP2K1, RAF1 | More | |
Chlorpheniramine | hsa04722 | Neurotrophin signaling pathway | 7.10E-03 | 4 | P04049, P49841, O43524, P48023 | RAF1, GSK3B, FOXO3, FASLG | More | |
Chlorpheniramine | hsa04725 | Cholinergic synapse | 4.83E-02 | 4 | P22694, Q14643, P18848, P10415 | PRKACB, ITPR1, ATF4, BCL2 | More | |
Chlorpheniramine | hsa04726 | Serotonergic synapse | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04730 | Long-term depression | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04810 | Regulation of actin cytoskeleton | 3.81E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04910 | Insulin signaling pathway | 2.51E-03 | 4 | P22694, P06737, P04049, P49841 | PRKACB, PYGL, RAF1, GSK3B | More | |
Chlorpheniramine | hsa04912 | GnRH signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
Chlorpheniramine | hsa04914 | Progesterone-mediated oocyte maturation | 1.91E-03 | 5 | Q17RY0, Q9Y6D9, P51812, Q02750, P04049 | CPEB4, MAD1L1, RPS6KA3, MAP2K1, RAF1 | More | |
Chlorpheniramine | hsa04915 | Estrogen signaling pathway | 3.15E-02 | 6 | P14780, P22694, P04049, P18848, Q14643, P10415 | MMP9, PRKACB, RAF1, ATF4, ITPR1, BCL2 | More | |
Chlorpheniramine | hsa04916 | Melanogenesis | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04917 | Prolactin signaling pathway | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04918 | Thyroid hormone synthesis | 3.50E-02 | 3 | P22694, P18848, Q14643 | PRKACB, ATF4, ITPR1 | More | |
Chlorpheniramine | hsa04919 | Thyroid hormone signaling pathway | 6.83E-04 | 5 | P49841, P04049, P22694, O60244, Q9NVC6 | GSK3B, RAF1, PRKACB, MED14, MED17 | More | |
Chlorpheniramine | hsa04921 | Oxytocin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
Chlorpheniramine | hsa04926 | Relaxin signaling pathway | 6.24E-03 | 5 | P18848, P22694, P14780, P04049, P30679 | ATF4, PRKACB, MMP9, RAF1, GNA15 | More | |
Chlorpheniramine | hsa04927 | Cortisol synthesis and secretion | 4.44E-04 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | |
Chlorpheniramine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 9.56E-03 | 6 | Q14643, P22694, P23771, P04049, P18848, P10415 | ITPR1, PRKACB, GATA3, RAF1, ATF4, BCL2 | More | |
Chlorpheniramine | hsa04929 | GnRH secretion | 4.98E-03 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
Chlorpheniramine | hsa04932 | Non-alcoholic fatty liver disease | 6.73E-05 | 9 | P01375, P49841, P18848, P48023, P01584, P13073, O15239, Q16718, O14521 | TNF, GSK3B, ATF4, FASLG, IL1B, COX4I1, NDUFA1, NDUFA5, SDHD | More | |
Chlorpheniramine | hsa04935 | Growth hormone synthesis, secretion and action | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Chlorpheniramine | hsa04961 | Endocrine and other factor-regulated calcium reabsorption | 2.68E-02 | 3 | P20020, Q9UEF7, P17252 | ATP2B1, KL, PRKCA | More | |
Chlorpheniramine | hsa04966 | Collecting duct acid secretion | 1.68E-02 | 2 | P02730, P00918 | SLC4A1, CA2 | More | |
Chlorpheniramine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
Chlorpheniramine | hsa04972 | Pancreatic secretion | 2.68E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | |
Chlorpheniramine | hsa04976 | Bile secretion | 1.67E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | |
Chlorpheniramine | hsa05012 | Parkinson disease | 2.53E-02 | 5 | O15239, P13073, P05141, P18848, Q13557 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D | More | |
Chlorpheniramine | hsa05016 | Huntington disease | 3.21E-02 | 5 | O15239, P13073, P30876, P62487, P05141 | NDUFA1, COX4I1, POLR2B, POLR2G, SLC25A5 | More | |
Chlorpheniramine | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | |
Chlorpheniramine | hsa05020 | Prion disease | 3.73E-04 | 11 | P13591, P01584, P11142, O15239, Q16718, O14521, P13073, P18848, P05141, P49841, Q16539 | NCAM1, IL1B, HSPA8, NDUFA1, NDUFA5, SDHD, COX4I1, ATF4, SLC25A5, GSK3B, MAPK14 | More | |
Chlorpheniramine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.47E-03 | 12 | P49841, O15239, Q16718, O14521, P13073, P18848, Q13561, P05141, Q16539, P01584, Q08752, Q13557 | GSK3B, NDUFA1, NDUFA5, SDHD, COX4I1, ATF4, DCTN2, SLC25A5, MAPK14, IL1B, PPID, CAMK2D | More | |
Chlorpheniramine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
Chlorpheniramine | hsa05034 | Alcoholism | 1.81E-06 | 8 | Q13547, P04049, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, RAF1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Chlorpheniramine | hsa05100 | Bacterial invasion of epithelial cells | 2.85E-02 | 3 | Q14141, Q05397, Q96JJ3 | SEPT6, PTK2, ELMO2 | More | |
Chlorpheniramine | hsa05132 | Salmonella infection | 5.10E-03 | 12 | P51617, P04049, Q9UJU2, Q13546, Q13489, P10415, O75369, O60603, Q9BQS8, Q13561, Q13509, P68371 | IRAK1, RAF1, LEF1, RIPK1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DCTN2, TUBB3, TUBB2C | More | |
Chlorpheniramine | hsa05133 | Pertussis | 4.94E-02 | 1 | P0C0L4 | C4A | More | |
Chlorpheniramine | hsa05134 | Legionellosis | 1.28E-02 | 3 | P01584, P68104, P11142 | IL1B, EEF1A1, HSPA8 | More | |
Chlorpheniramine | hsa05135 | Yersinia infection | 3.29E-02 | 4 | Q05397, P51812, Q02750, Q96JJ3 | PTK2, RPS6KA3, MAP2K1, ELMO2 | More | |
Chlorpheniramine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
Chlorpheniramine | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | |
Chlorpheniramine | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
Chlorpheniramine | hsa05152 | Tuberculosis | 1.40E-02 | 9 | P04049, Q13488, P48382, P25208, O60603, P10415, P01568, Q9UDY8, P51617 | RAF1, TCIRG1, RFX5, NFYB, TLR2, BCL2, IFNA21, MALT1, IRAK1 | More | |
Chlorpheniramine | hsa05160 | Hepatitis C | 1.40E-03 | 5 | P60033, P04049, P49841, P01375, P48023 | CD81, RAF1, GSK3B, TNF, FASLG | More | |
Chlorpheniramine | hsa05161 | Hepatitis B | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | |
Chlorpheniramine | hsa05163 | Human cytomegalovirus infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05164 | Influenza A | 3.65E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 3.15E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05170 | Human immunodeficiency virus 1 infection | 5.63E-03 | 11 | P04049, P62873, P17252, Q13546, Q14643, P01568, P51617, O60603, Q13315, P10415, Q9Y6Q5 | RAF1, GNB1, PRKCA, RIPK1, ITPR1, IFNA21, IRAK1, TLR2, ATM, BCL2, AP1M2 | More | |
Chlorpheniramine | hsa05171 | Coronavirus disease - COVID-19 | 9.72E-03 | 7 | P01584, P62753, P25398, P36578, P32969, P18077, P62829 | IL1B, RPS6, RPS12, RPL4, RPL9, RPL35A, RPL23 | More | |
Chlorpheniramine | hsa05202 | Transcriptional misregulation in cancer | 1.12E-04 | 20 | Q12778, Q15532, Q13315, P14780, P27930, P14923, Q15744, Q16548, P11215, Q13489, Q13077, O15550, P35226, P05164, P12838, P08246, Q9C0K0, Q13547, P12980, P24522 | FOXO1, SS18, ATM, MMP9, IL1R2, JUP, CEBPE, BCL2A1, ITGAM, BIRC3, TRAF1, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, HDAC1, LYL1, GADD45A | More | |
Chlorpheniramine | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | |
Chlorpheniramine | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Chlorpheniramine | hsa05205 | Proteoglycans in cancer | 8.14E-04 | 13 | Q13009, Q14643, O75369, P04049, P14780, P17252, O60603, P01375, P23588, P04628, Q13635, P22694, P08962 | TIAM1, ITPR1, FLNB, RAF1, MMP9, PRKCA, TLR2, TNF, EIF4B, WNT1, PTCH1, PRKACB, CD63 | More | |
Chlorpheniramine | hsa05206 | MicroRNAs in cancer | 3.15E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05210 | Colorectal cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05211 | Renal cell carcinoma | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05212 | Pancreatic cancer | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05213 | Endometrial cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05214 | Glioma | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05218 | Melanoma | 9.63E-04 | 4 | P09619, Q9GZP0, Q02750, P04049 | PDGFRB, PDGFD, MAP2K1, RAF1 | More | |
Chlorpheniramine | hsa05219 | Bladder cancer | 4.98E-03 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05220 | Chronic myeloid leukemia | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05221 | Acute myeloid leukemia | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05223 | Non-small cell lung cancer | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05224 | Breast cancer | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05226 | Gastric cancer | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05230 | Central carbon metabolism in cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05231 | Choline metabolism in cancer | 1.49E-03 | 5 | Q02750, P04049, P09619, Q9GZP0, O15245 | MAP2K1, RAF1, PDGFRB, PDGFD, SLC22A1 | More | |
Chlorpheniramine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
Chlorpheniramine | hsa05321 | Inflammatory bowel disease | 1.19E-03 | 6 | P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | |
Chlorpheniramine | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Chlorpheniramine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Chlorpheniramine | hsa05332 | Graft-versus-host disease | 1.91E-05 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | |
Chlorpheniramine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 3.10E-02 | 3 | Q8IZS8, P54284, P13612 | CACNA2D3, CACNB3, ITGA4 | More | |
Chlorpheniramine | hsa05414 | Dilated cardiomyopathy | 2.11E-02 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | |
Chlorpheniramine | hsa05415 | Diabetic cardiomyopathy | 1.02E-03 | 8 | P05141, O15239, Q16718, O14521, P13073, Q16539, P49841, Q13557 | SLC25A5, NDUFA1, NDUFA5, SDHD, COX4I1, MAPK14, GSK3B, CAMK2D | More | |